190 related articles for article (PubMed ID: 11061604)
1. Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling.
Kollmannsberger C; Nichols C; Meisner C; Mayer F; Kanz L; Bokemeyer C
Ann Oncol; 2000 Sep; 11(9):1115-20. PubMed ID: 11061604
[TBL] [Abstract][Full Text] [Related]
2. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors.
Hartmann JT; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Bokemeyer C
Ann Oncol; 2002 Jul; 13(7):1017-28. PubMed ID: 12176779
[TBL] [Abstract][Full Text] [Related]
3. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
[TBL] [Abstract][Full Text] [Related]
4. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
[TBL] [Abstract][Full Text] [Related]
5. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.
Fizazi K; Culine S; Kramar A; Amato RJ; Bouzy J; Chen I; Droz JP; Logothetis CJ
J Clin Oncol; 2004 Oct; 22(19):3868-76. PubMed ID: 15302906
[TBL] [Abstract][Full Text] [Related]
6. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).
Daugaard G; Skoneczna I; Aass N; De Wit R; De Santis M; Dumez H; Marreaud S; Collette L; Lluch JRG; Bokemeyer C; Schmoll HJ
Ann Oncol; 2011 May; 22(5):1054-1061. PubMed ID: 21059637
[TBL] [Abstract][Full Text] [Related]
8. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in metastatic nonseminomatous germ cell tumours.
Hanson PR; Belitsky P; Millard OH; Lannon SG
Can J Surg; 1993 Dec; 36(6):537-40. PubMed ID: 7504978
[TBL] [Abstract][Full Text] [Related]
10. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
11. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
Toner GC; Geller NL; Lin SY; Bosl GJ
Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
[TBL] [Abstract][Full Text] [Related]
12. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
Aass N; Klepp O; Cavallin-Stahl E; Dahl O; Wicklund H; Unsgaard B; Baldetorp L; Ahlström S; Fosså SD
J Clin Oncol; 1991 May; 9(5):818-26. PubMed ID: 1707957
[TBL] [Abstract][Full Text] [Related]
15. Mediastinal metastases from testicular nonseminomatous germ cell tumors: patterns of dissemination and predictors of long-term survival with surgery.
Kesler KA; Brooks JA; Rieger KM; Fineberg NS; Einhorn LH; Brown JW
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):913-23. PubMed ID: 12698156
[TBL] [Abstract][Full Text] [Related]
16. Extragonadal germ cell tumors: relation to testicular neoplasia and management options.
Bokemeyer C; Hartmann JT; Fossa SD; Droz JP; Schmol HJ; Horwich A; Gerl A; Beyer J; Pont J; Kanz L; Nichols CR; Einhorn L
APMIS; 2003 Jan; 111(1):49-59; discussion 59-63. PubMed ID: 12752235
[TBL] [Abstract][Full Text] [Related]
17. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
Mead GM; Stenning SP; Parkinson MC; Horwich A; Fossa SD; Wilkinson PM; Kaye SB; Newlands ES; Cook PA
J Clin Oncol; 1992 Jan; 10(1):85-94. PubMed ID: 1309383
[TBL] [Abstract][Full Text] [Related]
18. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.
Bokemeyer C; Nichols CR; Droz JP; Schmoll HJ; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Kanz L; Einhorn L; Hartmann JT
J Clin Oncol; 2002 Apr; 20(7):1864-73. PubMed ID: 11919246
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
20. Further advances in the management of malignant teratomas of the testis and other sites.
Newlands ES; Begent RH; Rustin GJ; Parker D; Bagshawe KD
Lancet; 1983 Apr; 1(8331):948-51. PubMed ID: 6188011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
